Role of urinary aquaporin 2 in evaluating proximal tubular injury

doi:10.3969/j.issn.1673-8640.2019.07.012

Abstract

Abstract:

Objective To investigate the role of urinary aquaporin 2（AQP₂） in evaluating proximal tubular injury. Methods A total of 353 healthy subjects were enrolled as healthy control group,and 70 hypertensive nephrotic patients were enrolled and classified into edema group（38 cases） and non-edema group（32 cases）. Their general data were collected,and urinary AQP₂,urinary alpha₁-microglobulin（α₁-MG）,beta₂-microglobulin（β₂-MG）,serum creatinine（SCr）,serum cystatin C（Cys C） levels were determined. Receiver operating characteristic（ROC） curve was used to evaluate the role of urinary AQP₂ for the diagnosis of proximal tubular injury. Results Urinary AQP₂ showed skewed distribution,and its level was 9.42（6.96-13.95） ng/mL. The reference interval was ≤19.11 ng/mL. The level of urinary AQP₂ in nephrotic group was higher than that in healthy control group（P<0.01）,and the levels of urinary AQP₂,α₁-MG and β₂-MG in edema group were higher than those in non-edema group（P<0.01）. There was no statistical significance for body mass index（BMI）,SCr,serum Cys C between the 2 groups（P>0.05）. ROC curve analysis showed that the areas under the curves（AUC） for the diagnosis of kidney disease and edema were 0.93 and 0.83,the optimal cut-off values were 18.12 and 26.93 ng/mL,the sensitivities were 81.43% and 71.05%,and the specificities were 92.63% and 81.25%,respectively. The AUC of α₁-MG and β₂-MG for the diagnosis of edema were 0.80 and 0.69,respectively. The AUC of urinary AQP₂ combined with α₁-MG and β₂-MG for the detection of nephrotic edema is 0.91,the sensitivity is 86.84%,and the specificity is 87.50%. Conclusions Urinary AQP₂ can be used as a sensitive indicator in evaluating proximal tubular injury.

Key words: Aquaporin 2, Urine, Proximal tubular injury, Kidney disease

CLC Number:

R446.1

WANG Xueying, LIU Huan, ZHOU Xiang, YANG Ruofan, WANG Chun'e, MA Lian, BAI Bifeng, LI Feng. Role of urinary aquaporin 2 in evaluating proximal tubular injury[J]. Laboratory Medicine, 2019, 34(7): 626-629.

Figures/Tables 5

References 13

[1]	AGRE P,KING L S,YASUI M,et al.Aquaporin water channels-from atomic structure to clinical medicine[J]. J Physiol,2002,542(Pt 1):3-16.
[2]	王昱,张清,陈凯,等. 原发性肾病综合征患者尿水通道蛋白异常及其意义[J]. 中国中西医结合肾病杂志,2013,14(12):1055-1058.
[3]	刘青,李锋,任秦有,等. 大黄总蒽醌含药血清对NRK细胞AQP2与AQP4表达的调节效应[J]. 中国中西医结合肾病杂志,2009,10(9):812-815.
[4]	National Kidney Foundation.KDOQI clinical practice guideline for diabetes and CKD:2012 update[J]. Am J Kidney Dis,2012,60(5):850-886.
[5]	《中国高血压防治指南》修订委员会. 中国高血压防治指南(2005年修订版)[M]. 北京:人民卫生出版社,2006:19-20.
[6]	王力宁,姚丽. 高血压性肾损害[J]. 中华肾脏病杂志,2005,21(10):569-571.
[7]	刘志红,黎磊石. 糖尿病肾病发病机理[J]. 中华肾脏病杂志,1999,15(2):120.
[8]	解冰,江利萍. 肾小管标记物测定在慢性肾功能不全病人中的结果探讨[J]. 医学检验与临床,2006,17(6):15-16.
[9]	董晓静,郭亮锋,姚锐,等. 丹参调节肾组织AQP2效应与其“活血利尿”关系[J]. 中国中药杂志,2014,39(16):3162-3165.
[10]	MATSUZAKI T,YAGUCHI T,SHIMIZU K,et al.The distribution and function of aquaporins in the kidney: resolved and unresolved questions[J]. Anat Sci Int,2017,92(2):187-199.
[11]	TANAKA A,NAKAMURA T,SATO E,et al.Aquaporin-2 is a potential biomarker for tolvaptan efficacy in decompensated heart failure complicated by diabetic nephrotic syndrome[J]. Int J Cardiol,2016,210:1-3.
[12]	WANG Y,BU J,ZHANG Q,et al.Expression pattern of aquaporins in patients with primary nephrotic syndrome with edema[J]. Mol Med Rep,2015,12(4):5625-5632.
[13]	黄和贤,曹文富. “肾主水”与肾病性水代谢紊乱及肾水通道蛋白2关系探讨[J]. 实用中医药杂志,2011,27(12):870-872.

AQP₂（ng/mL）	频数	累计频数	累计频率（%）
2.9~	17	17	4.81
4.9~	68	85	24.08
6.9~	84	169	47.87
8.9~	32	201	56.94
10.9~	36	237	67.14
12.9~	41	278	78.75
14.9~	29	307	86.97
16.9~	27	334	94.62
18.9~	13	347	98.30
20.9~	6	353	100

AQP₂（ng/mL）	频数	累计频数	累计频率（%）
2.9~	17	17	4.81
4.9~	68	85	24.08
6.9~	84	169	47.87
8.9~	32	201	56.94
10.9~	36	237	67.14
12.9~	41	278	78.75
14.9~	29	307	86.97
16.9~	27	334	94.62
18.9~	13	347	98.30
20.9~	6	353	100

组别	例数	年龄（岁）	性别		BMI（kg/m²）	Cys C（mg/L）
组别	例数	年龄（岁）	男（例）	女（例）	BMI（kg/m²）	Cys C（mg/L）
水肿组	38	60.02±15.43	20	18	25.9±4.7	1.28±0.57
非水肿组	32	53.72±19.17	19	13	23.9±4.1	1.21±0.53
组别	SCr（μmol/L）		AQP₂（ng/mL）		α₁-MG（mg/L）	β₂-MG（mg/L）
水肿组	104.26±45.38		35.77（23.97~48.44）		38.50（22.35~60.80）	5.25（0.25~19.25）
非水肿组	106.25±57.28		19.90（15.14~25.93）^*		8.94（5.15~29.60）^*	0.29（0.20~2.163）^*

组别	例数	年龄（岁）	性别		BMI（kg/m²）	Cys C（mg/L）
组别	例数	年龄（岁）	男（例）	女（例）	BMI（kg/m²）	Cys C（mg/L）
水肿组	38	60.02±15.43	20	18	25.9±4.7	1.28±0.57
非水肿组	32	53.72±19.17	19	13	23.9±4.1	1.21±0.53
组别	SCr（μmol/L）		AQP₂（ng/mL）		α₁-MG（mg/L）	β₂-MG（mg/L）
水肿组	104.26±45.38		35.77（23.97~48.44）		38.50（22.35~60.80）	5.25（0.25~19.25）
非水肿组	106.25±57.28		19.90（15.14~25.93）^*		8.94（5.15~29.60）^*	0.29（0.20~2.163）^*

[1]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[2]	WANG Gangqiang, DIAO Yanjun, HE Juan, YANG Ruofan, YAN Hongbin, WANG Pei, LU Pei, LI Chenghua, XIAO Fengjing, ZHENG Shanluan, HAO Xiaoke, CHENG Xiang, LIU Jiayun. Establishment，verification and clinical application of automatic urine analysis system audit rule [J]. Laboratory Medicine, 2023, 38(10): 957-966.
[3]	WU Yating, LI Zhuolin, LEI Yan, JIA Ruxue, ZHANG Shenghang, WANG Shuiliang. Research progress of miRNA in urine as a biomarker for common malignant tumors [J]. Laboratory Medicine, 2023, 38(1): 94-99.
[4]	PAN Fen, PAN Yuxuan, SHI Yingying, YU Fangyuan, ZHANG Hong. UroQuick rapid urine culture technique for urinary tract infection in children [J]. Laboratory Medicine, 2022, 37(7): 652-656.
[5]	HE Tianwen, LU Jian, CHEN Chuangqi, LIU Dun, DING Hongke, LIU Ling, DU Li, ZHENG Yichun, YIN Aihua. Preimplantation genetic testing of infantile polycystic kidney disease by next generation sequencing [J]. Laboratory Medicine, 2022, 37(3): 257-263.
[6]	MAO Jie, LU Qingqing, LI Ping, SHI Shengjie, LI Jing, DENG Changjuan, TAN Chaochao, XIE Xiaobing. Research progress of clinical application of copeptin in different diseases [J]. Laboratory Medicine, 2022, 37(3): 291-294.
[7]	Danqu, Luosangcizhen, Zerenqucuo, MA Chaochao, LIU Zhijuan. Combined detection of urinary total protein to avoid the hook effect of urinary microalbumin [J]. Laboratory Medicine, 2021, 36(5): 477-479.
[8]	XIE Hui, SHEN Han. Changes of coagulation function and influence factors of hypercoagulability in patients with chronic kidney disease [J]. Laboratory Medicine, 2021, 36(5): 500-503.
[9]	WU Huiwen, LI Luoping, XING Xiaozhong, WAN Dayong. Clinical value of combined detection of RBP,CRP and UMA in patients with chronic renal disease and ischemic cerebrovascular disease [J]. Laboratory Medicine, 2021, 36(3): 304-308.
[10]	WANG Jinduo, CUI Yunqing, ZHANG Hui, Yanhua, LI Yinghua. Effect of vulva cleaning operation to the determination results of urinary biochemical indexes [J]. Laboratory Medicine, 2021, 36(11): 1169-1171.
[11]	XIAO Nan, ZHOU Jia, DUAN Ning, ZHU Tianyang, WANG Lijun. Establishment and evaluation of fast predictive algorithm for urinary tract infection pathogen in patients with nephrolithiasis [J]. Laboratory Medicine, 2021, 36(1): 75-79.
[12]	ZHOU Xin, ZHANG Jue, CHEN Liying. Study on the main causes for false increasing of white blood cells and small round epithelial cells determined by UF-1000i urine sediment analyzer [J]. Laboratory Medicine, 2020, 35(5): 444-446.
[13]	ZHOU Xin, ZHANG Jue, CHEN Liying. Study on the main causes for false increasing of white blood cells and small round epithelial cells determined by UF-1000i urine sediment analyzer [J]. Laboratory Medicine, 2020, 35(5): 444-446.
[14]	YANG Meiling, LIU Hao, YANG Lin, ZHU Ping. Research progress on the biomarkers of urinary tract infection [J]. Laboratory Medicine, 2020, 35(2): 178-180.
[15]	CHEN Xu, FENG Juan, HU Xiaobo, WANG Changfu. Research progress of pseudouridine as a biomarker of kidney disease and cancer [J]. Laboratory Medicine, 2019, 34(9): 864-867.